Phuturdex › Diseases › Dyslipidemia
Drugs in development · updated 30 October 2026
Dyslipidemia: drugs in development
As of 30 October 2026 there are 31 active clinical trials (recruiting or ongoing, phases I–III) on 35 drugs for dyslipidemia. 23 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AZD0780 | II–III | 1 | NCT06834932 |
| BERLIM 25 | III | 1 | NCT04602754 |
| C2402 | III | 1 | NCT06643130 |
| C2403 | III | 1 | NCT06643130 |
| CMG190303 | III | 1 | NCT06772168 |
| JW0104 | III | 1 | NCT06643130 |
| Zodasiran | III | 1 | NCT07473843 |
| EDP167 | II | 2 | NCT07799129 |
| DII235 | II | 1 | NCT07235046 |
| ObicetrapibUbeslo® | II | 1 | NCT06496243 |
| RBD5044 | II | 1 | NCT06797401 |
| AD-231 | I | 1 | NCT07590167 |
| AD-231A | I | 1 | NCT07590167 |
| AD-231C | I | 1 | NCT07590167 |
| AD-231D | I | 1 | NCT07590167 |
| AZD1705 | I | 1 | NCT06238466 |
| AZD4954 | I | 1 | NCT06980428 |
| BSA204 | I | 1 | NCT07551505 |
| CTX310 | I | 1 | NCT07491172 |
| ECC4703 | I | 1 | NCT07726368 |
| HS-10582 | I | 1 | NCT07777003 |
| MWX205 | I | 1 | NCT07634510 |
| RS-C1001 | I | 1 | NCT06669429 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| InclisiranLeqvio® | III | 5 | NCT05739383 |
| RosuvastatinEzallor Sprinkle®, Crestor® | II–III | 4 | NCT06834932 |
| AtorvastatinLipitor, Atorvaliq® | III | 2 | NCT07045142 |
| EmpagliflozinJardiance | III | 1 | NCT04602754 |
| LerodalcibepLyrokaul® | III | 1 | NCT06568471 |
| MetforminRiomet Er®, Glumetza® | III | 1 | NCT07045142 |
| ResmetiromMGL-3196, Rezdiffra® | III | 1 | NCT04951219 |
| Bempedoic acidNexletol®, Nilemdo® | II | 1 | NCT05488431 |
| ColchicineColchicin, Lodoco® | II | 1 | NCT07654231 |
| EvolocumabRepatha | II | 1 | NCT06496243 |
| PitavastatinNikita®, Zypitamag® | I | 1 | NCT07726368 |
| SulfasalazineAzulfidine En-Tabs®, Azulfidine® | I | 1 | NCT07726368 |
Sorted by most advanced phase and number of active trials.
All 35 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Hyperlipidemia 26 drugs
- Hypercholesterolemia 21 drugs
- Hypertriglyceridemia 18 drugs
- Hyperlipoproteinemia Type II 12 drugs
- Homozygous familial hypercholesterolemia 7 drugs
- Coronary artery disease 34 drugs
- Arterial hypertension 119 drugs
- Type 2 diabetes 171 drugs
- Cardiovascular disease 71 drugs
- Pancreatitis 15 drugs
- Metabolic syndrome 12 drugs
- Obesity 233 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Lipid metabolism disorder 4 drugs
- Metabolic disease 30 drugs
- Vascular disease 16 drugs
- Genetic disease 33 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D050171 “Dyslipidemias”.